Insights - A week after the FDA modified a similar restriction on Tekmira Pharmaceuticals (TKMR), the federal agency has cleared Arrowhead Research (ARWR) to proceed with a multiple-dose Phase 2b clinical study … Continue Reading
Read NowInsights - The talk of a bubble in biotech seems to have subsided (temporarily, no doubt), and the sector-tracking iShares Nasdaq Biotech ETF (IBB) has continued higher … Continue Reading
Read NowInsights - Almost three years after an initial collaboration was announced, AstraZeneca (AZN) has selected the first clinical candidate from a discovery program with Regulus Therapeutics (RGLS). RGLS jumped … Continue Reading
Read NowInsights - Dyax Corp. (DYAX) saw a gain of over 40% in pre-market trading Wednesday with the release of phase 1b results for DX-2930, an inhibitor of … Continue Reading
Read NowInsights - Monday morning was jam-packed with deal flow in biotech. Here's a 60-second primer.
Read NowInsights - Top-line results from Ohr Pharmaceuticals’ (OHRP) phase II IMPACT study, testing its squalamine eyedrops in age-related macular degeneration (wet-AMD), had a crushing effect on the stock Friday. … Continue Reading
Read NowInsights - VBL Therapeutics (VBLT) claimed success in a trial of lead drug candidate VB-111 in brain cancer on Wednesday, sending the stock higher by 40% in early trading.
Read Now
